Systemic and Brain Pharmacokinetics of Perforin Inhibitor Prodrugs

We have recently reported that by converting a perforin inhibitor into an L-type amino acid transporter 1 (LAT1)-utilizing prodrug its cellular uptake can be greatly increased. The aim of the present study was to determine the in vivo and brain pharmacokinetics of two perforin inhibitors and their LAT1-utilizing prodrugs 1 and 2. In addition, the brain uptake mechanism and entry into primary mouse cortical neurons and astrocytes were evaluated. After 23 mu mol/kg i.p. bolus injection, the prodrugs' unbound area under the concentration curve in brain was 0.3 nmol/g x min, whereas the parent drugs could not reach the brain. The unbound brain concentrations of the prodrugs after 100 mu M in situ mouse brain perfusion were 521.4 +/- 46.9 and 126.9 +/- 19.9 pmol/g for prodrugs 1 and 2, respectively. The combination of competing transporter substrates for LAT1, L-tryptophan, and for organic anion transporting polypeptides, probenecid, decreased the brain concentrations to 352.4 +/- 44.5 and 70.9 +/- 7.0 pmol/g, respectively. In addition, in vitro uptake studies showed that at 100 mu M prodrug 1 had 3.4-fold and 4.5-fold higher uptake rate into neurons and astrocytes, respectively, compared to its parent drug. Thus, the prodrugs enhance significantly the therapeutic potential of the parent drugs for the treatment of disorders of central nervous system in which neuroinflammation is involved.